122 related articles for article (PubMed ID: 12694666)
21. Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection.
Kahan BD; Stepkowski S; Kilic M; Katz SM; Van Buren CT; Welsh MS; Tami JA; Shanahan WR
Transplantation; 2004 Sep; 78(6):858-63. PubMed ID: 15385805
[TBL] [Abstract][Full Text] [Related]
22. A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma.
Cunningham CC; Holmlund JT; Geary RS; Kwoh TJ; Dorr A; Johnston JF; Monia B; Nemunaitis J
Cancer; 2001 Sep; 92(5):1265-71. PubMed ID: 11571742
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer.
Estes JM; Leath CA; Williams S; Modiano MR; Sawyer M; Cohn D; Straughn JM; Barnes MN; Alvarez RD
Gynecol Oncol; 2006 Aug; 102(2):338-42. PubMed ID: 16487997
[TBL] [Abstract][Full Text] [Related]
24. A phase II trial of edatrexate in previously treated ovarian cancer. A Gynecologic Oncology Group study.
Broun ER; Iseminger KA; Bookman M
Am J Clin Oncol; 1995 Apr; 18(2):164-6. PubMed ID: 7900709
[TBL] [Abstract][Full Text] [Related]
25. Technology evaluation: alicaforsen (Isis).
Gewirtz AT; Sitaraman SV
Curr Opin Mol Ther; 2005 Jun; 7(3):273-81. PubMed ID: 15977426
[TBL] [Abstract][Full Text] [Related]
26. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.
Brown JV; Peters WA; Rettenmaier MA; Karlan BY; Dillman RA; Smith MR; Drescher CW; Micha JP
Gynecol Oncol; 2000 Dec; 79(3):495-8. PubMed ID: 11104627
[TBL] [Abstract][Full Text] [Related]
27. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
O'Malley DM; Azodi M; Makkenchery A; Tangir J; McAlpine J; Kelly M; Schwartz P; Rutherford T
Gynecol Oncol; 2005 Aug; 98(2):242-8. PubMed ID: 15992916
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of fazarabine in patients with advanced ovarian cancer. A Gynecologic Oncology Group study.
Manetta A; Blessing JA; Look KY
Am J Clin Oncol; 1995 Apr; 18(2):156-7. PubMed ID: 7534978
[TBL] [Abstract][Full Text] [Related]
29. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
Herzog TJ; Powell MA; Rader JS; Gibb R; Mutch DG
Gynecol Oncol; 2006 Nov; 103(2):637-41. PubMed ID: 16781766
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T
Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
[TBL] [Abstract][Full Text] [Related]
31. A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.
Look KY; Blessing JA; Adelson MD; Morris M; Bookman MA
Am J Clin Oncol; 1996 Feb; 19(1):7-9. PubMed ID: 8554040
[TBL] [Abstract][Full Text] [Related]
32. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis.
Maksymowych WP; Blackburn WD; Tami JA; Shanahan WR
J Rheumatol; 2002 Mar; 29(3):447-53. PubMed ID: 11908555
[TBL] [Abstract][Full Text] [Related]
33. Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients.
Denschlag D; Watermann D; Hörig K; Kissel C; Tempfer C; Gitsch G
Anticancer Res; 2004; 24(2C):1267-9. PubMed ID: 15154658
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
[TBL] [Abstract][Full Text] [Related]
35. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
[TBL] [Abstract][Full Text] [Related]
36. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
Bookman MA; Malmström H; Bolis G; Gordon A; Lissoni A; Krebs JB; Fields SZ
J Clin Oncol; 1998 Oct; 16(10):3345-52. PubMed ID: 9779711
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
Coleman RL; Broaddus RR; Bodurka DC; Wolf JK; Burke TW; Kavanagh JJ; Levenback CF; Gershenson DM
Gynecol Oncol; 2006 Apr; 101(1):126-31. PubMed ID: 16271384
[TBL] [Abstract][Full Text] [Related]
38. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
Dark GG; Calvert AH; Grimshaw R; Poole C; Swenerton K; Kaye S; Coleman R; Jayson G; Le T; Ellard S; Trudeau M; Vasey P; Hamilton M; Cameron T; Barrett E; Walsh W; McIntosh L; Eisenhauer EA
J Clin Oncol; 2005 Mar; 23(9):1859-66. PubMed ID: 15699482
[TBL] [Abstract][Full Text] [Related]
39. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).
Alberts DS; Liu PY; Wilczynski SP; Jang A; Moon J; Ward JH; Beck JT; Clouser M; Markman M
Int J Gynecol Cancer; 2007; 17(4):784-8. PubMed ID: 17343607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
